HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1873875IXHL stock profile & AI dashboard →

13F Pro Quality Score

12.3/100

Rank #2,888 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

IXHL Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Incannex Healthcare Inc. (IXHL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IXHL at 12.3/100 on a 32-signal composite quality model, placing it at rank #2,888 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2026), Incannex Healthcare Inc. reports net income of $-3.9M, free cash flow of $-2.5M. Top institutional holders of IXHL by reported 13-F value include LPL Financial, MILLENNIUM MANAGEMENT, JANE STREET GROUP, based on the most recent SEC filings. IXHL trades on the Nasdaq exchange and files with the SEC under CIK 1873875. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IXHL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Incannex Healthcare Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-3.9M

Free Cash Flow

Q1 2026

$-2.5M

ROIC

Q1 2026

-21.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+616.7% YoY
$86.0KFY 2025
FY22 FY23 FY24 $12.0KFY25 $86.0K

Net Income

-154.0% YoY
$-46.9MFY 2025
FY22 FY23 $-48.8MFY24 $-18.5MFY25 $-46.9M

Operating Income

+20.8% YoY
$-23.8MFY 2025
FY22 FY23 $-49.7MFY24 $-30.0MFY25 $-23.8M

EPS (Diluted)

-17.4% YoY
$-1.35FY 2025
FY22 FY23 $-3.32FY24 $-1.15FY25 $-1.35

Total Assets

+19.9% YoY
$20.4MFY 2025
FY22 $37.9MFY23 $23.8MFY24 $17.0MFY25 $20.4M

Op. Cash Flow

+21.0% YoY
$-12.5MFY 2025
FY22 FY23 $-10.7MFY24 $-15.8MFY25 $-12.5M

Free Cash Flow

+22.3% YoY
$-12.5MFY 2025
FY22 FY23 $-11.1MFY24 $-16.1MFY25 $-12.5M

Get alerted when IXHL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Incannex Healthcare Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put IXHL on your watchlist

Track score changes the day Incannex Healthcare Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is IXHL a good stock to buy?

13F Pro's AI-powered analysis of Incannex Healthcare Inc. (IXHL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IXHL are available on the IXHL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IXHL is classified as a small company.

Which hedge funds own IXHL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IXHL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Incannex Healthcare Inc.'s investment landscape.